Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This protocol will evaluate the efficacy of Therapeutic Plasma Exchange alone or in combination with ruxolitinib in COVID positive patients with PENN grade 2, 3, 4 cytokine release syndrome. It is hypothesized that dual intervention of acute apheretic depletion of cytokines and concomitant suppression of production will produce superior amelioration of the cytokine load and to help to prevent cytokine load rebound. This protocol is envisioned as a pilot study (n=20) for hypothesis generation for future investigation.
Description: Defined as greater than or equal to 33% decrease in cytokine load in one-third or more participants
Measure: Overall Response Rate Time: 14 days